ESMO World Congress on Gastrointestinal Cancer 2017

Oncology Meeting Resources

28 Jun - 01 Jul 2017, Barcelona, Spain

ESMO World GI 2017 square image

The ESMO World Congress on Gastrointestinal Cancer 2017 (World GI) is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts are open access. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Watch the ESMO scientific videos

Best Abstracts Session on Colorectal Cancer , Speaker: Filippo Pietrantonio

Tips for Practice: MSI Testing in GI Cancers , Speaker: Fatima Carneiro

Prevention of Colorectal Cancer , Speaker: Nadir Arber

The Role of Microbiome in Cancer Medicine , Speaker: James Godaert

All interviews from the event on the ESMO Channel





Format available

https://oncologypro.esmo.org/Meeting-Resour...lasm-an-experience-from-Rimini-City-Hospital

TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil, demonstrating efficacy in pre-treated metastatic colorectal cancer.

Date: 28 Jun 2017
Presenter: Claudio Ridolfi
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...HUCA-University-Hospital-Central-of-Asturias

Refractory metastatic colorectal cancer (defined as previous Pd or intolerance to anti-EGFR, anti-VEGF, irinotecan, oxaliplatin, and 5-Fu) is a clinical challenge as many patients maintain adequate...

Date: 28 Jun 2017
Presenter: Alfonso Revuelta
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...t-to-predict-capecitabine-serious-toxicities

Capecitabine is a fluoropyrimidine widely used to treat colorectal cancer and metastatic breast cancer. It is a prodrug converted to fluorouracil (FU), which is the active form.

Date: 28 Jun 2017
Presenter: Pilar Alonso
Resources: Abstract
Topic: Gastrointestinal Cancers

https://oncologypro.esmo.org/Meeting-Resour...es-mutations-in-metastatic-colorectal-cancer

Several studies have reported that right colon cancers (RCC) and left colon cancer (LCC) differ in several factors including genetic features. In our study, we investigated the association of tumor...

Date: 28 Jun 2017
Presenter: Marta Llanos Muñoz
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...omal-acidification-of-live-colon-cancer-cell

Lysosomal acidification is one of the micro-environmental changes of carcinogenesis pathophysiology. pH of lysosome is decreased from 4.5-6.0 to 3.8-4.7 as the normal cells become cancerous.

Date: 28 Jun 2017
Presenter: Geeho Min
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...tive-factors-for-surgery-in-stage-IV-MCRC-wt

Treatment for Stage IV MCRC (wt) remains palliative. However some p may achieve long term survival (LTS) with acceptable outcome. Complete Metastatic Surgery (CMS) is the most important therapy for LTS.

Date: 28 Jun 2017
Presenter: Damian Ortiz
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...tal-cancer-and-unresectable-liver-metastases

The optimal surgical strategy for treating colorectal cancer with stage IV is controversial. We evaluated the use of primary tumor resection in patients with stage IV colorectal cancer and unresectable liver metastases.

Date: 28 Jun 2017
Presenter: Isabel Pajares
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...gardless-of-BRAF-or-KRAS-mutational-profiles

No previous studies have evaluated clinical outcomes, such as BRAF/KRAS mutation profiles and microsatellite instability (MSI) statuses, of ovarian metastases of colorectal cancers (CRCs).

Date: 28 Jun 2017
Presenter: Takeshi Nagasaka
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...-patients-Sub-set-analysis-of-Polish-2-study

The prognostic role of blood morphology derrived parameters like neutrocyte-to-lymphocyte (NLR) or lymphocyte-to-monocyte (LMR) ratios was established in several cancers.

Date: 28 Jun 2017
Presenter: Mariola Winiarek
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...ith-high-risk-locally-advanced-rectal-cancer

Preoperative chemoradiation (CRT) and short-course radiotherapy are standard treatments for T3+ rectal tumours, but have adverse pelvic effects. NACT alone may reduce both local and systemic recurrences without causing long-term toxicity.

Date: 28 Jun 2017
Presenter: Marcia Hall
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer